Advanced search
Publication Cover
Hematology Volume 28, 2023 - Issue 1
Submit an article Journal homepage
12,802
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Long-term storage protocol of reagent red blood cells treated with 0.01M dithiothreitol (DTT) for pre-transfusion testing of patients receiving anti-CD38 therapy, daratumumab

Yuyuan Lia Department of Blood Transfusion, The First People’s Hospital of Foshan, Foshan, People’s Republic of China;b Department of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-1022-5820View further author information
ORCID Icon,
Chengyao Lib Department of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People’s Republic of ChinaView further author information
,
Ling Zhangb Department of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People’s Republic of ChinaView further author information
,
Jiao Lic Department of Laboratory, Shunde District Central Blood Station, Foshan, People’s Republic of ChinaView further author information
,
Qixin Lid Department of Clinical Laboratory, the First People's Hospital of Foshan, Foshan, People’s Republic of ChinaView further author information
,
Haining Ouyangc Department of Laboratory, Shunde District Central Blood Station, Foshan, People’s Republic of ChinaView further author information
,
Jiaona Luoc Department of Laboratory, Shunde District Central Blood Station, Foshan, People’s Republic of ChinaView further author information
,
Linrui Zhua Department of Blood Transfusion, The First People’s Hospital of Foshan, Foshan, People’s Republic of ChinaView further author information
&
Kui Caia Department of Blood Transfusion, The First People’s Hospital of Foshan, Foshan, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Article: 2186037 | Received 21 Nov 2022, Accepted 25 Feb 2023, Published online: 09 Mar 2023

References

  • Nijhof IS, van de Donk NWCJ, Zweegman S, et al. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs. 2018;78(1):19–37.
  • Albeniz I, Demir Ö, Türker-Şener L, et al. Erythrocyte CD38 as a prognostic marker in cancer. Hematology. 2007;12(5):409–414.
  • Mehta K, Shahid U, Malavasi F. Human CD38, a cell-surface protein with multiple functions. Faseb J. 1996;10(12):1408–1417.
  • Rajkumar SV, Kumar S. Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc. 2016;91(1):101–119.
  • Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–766.
  • Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55(6. Pt 2):1545–1554.
  • Chapuy CI, Aguad MD, Nicholson RT, et al. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing. Transfusion. 2016;56(12):2964–2972.
  • Lancman G, Arinsburg S, Jhang J, et al. Blood transfusion management for patients treated with anti-CD38 monoclonal antibodies. Front Immunol. 2018;9:2616.
  • Branch DR, Muensch HA, Hian ALSS, et al. Disulfide bonds are a requirement for kell and cartwright (Yta) blood group antigen integrity. Br J Haematol 1983;54(4):573–578.
  • Hosokawa M, Kashiwagi H, Nakayama K, et al. Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method). Transfusion. 2018;58(12):3003–3013.
  • Disbro WL. Stability guidelines for dithiothreitol-treated red blood cell reagents used for antibody detection methods in patients treated with daratumumab. Immunohematol. 2017;33(3):33–105.
  • Izaguirre EC, del Mar Luis-Hidalgo M, González LL, et al. New method for overcoming the interference produced by anti-CD38 monoclonal antibodies in compatibility testing. Blood Transfus. 2020;18(4):290–294.
  • Fung MK, Eder A, Spitalnik SL, et al. AABB technical manual. 19th ed. Bethesda (MD): American Association of Blood Banks; 2017.
  • Phou S, Costello C, Kopko PM, et al. Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens. Transfusion. 2021;61(7):2054–2063.
  • Ye Z, Wolf LA, Mettman D, et al. Risk of RBC alloimmunization in multiple myeloma patients treated by daratumumab. Vox Sang 2020;115(2):207–212.
  • Schmidt AE, Kirkley S, Patel N, et al. An alternative method to dithiothreitol treatment for antibody screening in patients receiving daratumumab. Transfusion. 2015;55(9):2292–2293.
  • Anani WQ, Duffer K, Kaufman RM, et al. How do I work up pretransfusion samples containing anti-CD38? Transfusion. 2017;57(6):1337–1342.
  • Tzogani K, Penninga E, Schougaard Christiansen ML, et al. EMA review of daratumumab for the treatment of adult patients with multiple myeloma. Oncologist. 2018;23(5):594–602.
  • Sullivan HC, Gerner-Smidt C, Nooka AK, et al. Daratumumab (anti-CD38) induces loss of CD38 on red blood cells. Blood. 2017;129(22):3033–3037.
  • Yu Y, Sun X, Guan X, et al. Effects of hydroformylation treatment on the storage time and blood group antigen expressions of reagent red blood cells. Transfus Apher Sci. 2014;50(3):462–466.
  • Söderberg J, Jonsson PA, Wallin O, et al. Haemolysis index – an estimate of preanalytical quality in primary health care. Clin Chem Lab Med 2009;47(8):940–944.
  • Reid ME L-FC, Olsson ML. The blood group antigen facts book. 3rd ed. Waltham (MA): Academic Press; 2012.
  • Sigle J-P, Mihm B, Suna R, et al. Extending shelf life of dithiothreitol-treated panel RBCs to 28 days. Vox Sang 2018;113(4):397–399.
  • Hugan SL, Cooling L, Larsson VM. An evaluation of storage time for dithiothreitol-treated reagent cells. Transfusion. 2017;57(10):2545–2546.
  • Wagner FF. Antibody testing in patients treated with anti-CD38: there is still room for improvement. Blood Transfus. 2020;18(4):244–246.
  • Chami B, Okuda M, Moayeri M, et al. Anti-CD38 monoclonal antibody interference with blood compatibility testing: differentiating isatuximab and daratumumab via functional epitope mapping. Transfusion. 2022;62(11):2334–2348.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.